* Die Links zu allen hier aufgeführen Abstracts sind externe Links und öffnen sich in einem neuen Fenster.

2010

Noetzel E, Rose M, Sevinc E, Hilgers RD, Hartmann A, Naami A, Knüchel R, Dahl E. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse. Oncogene. 2010 29:4814-25.
Abstract

Kristiansen G, Rose M, Geisler C, Fritzsche FR, Gerhardt J, Lüke C, Ladhoff AM, Knüchel R, Dietel M, Moch H, Varga Z, Theurillat JP, Gorr TA, Dahl E. Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype. Br J Cancer. 2010 102:1736-45.
Abstract

Veeck J, Dahl E. RNA expression analysis on formalin-fixed paraffin-embedded tissues in TMA format by RNA in situ hybridization. Methods Mol Biol. 2010 664:135-50.
Abstract

Antony P, Rose M, Gaisa NT, Alkaya S, Heidenreich A, Knüchel R, Dahl E. Characterisation of DNA methylation biomarkers for bladder cancer. Pathologe. 2010 Aug 28. [Epub ahead of print] German.
Abstract

Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, Chekerov R, Braicu I, Lichtenegger W, Sehouli J. Expression and localization of e-cadherin in epithelial ovarian cancer. Anticancer Res. 2010 7:2525-30.
Abstract

Knüchel-Clarke R, Dahl E, Gaisa NT, Schwamborn K, Lindemann-Docter K, Henkel C.
Current knowledge in molecular pathology of urothelial cancer. Pathologe. 2010 Jul 29. [Epub ahead of print] German.
Abstract

2009

Dahl E, En-Nia A, Wiesmann F, Krings R, Djudjaj S, Breuer E, Fuchs T, Wild PJ, Hartmann A, Dunn SE, Mertens PR. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer. 2009 9:410. * (Highly accessed)
Abstract

ten Haaf A, Bektas N, von Serenyi S, Losen I, Arweiler EC, Hartmann A, Knüchel R, Dahl E. Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. BMC Cancer. 2009 9:298. * (Highly accessed)
Abstract

Verjans E, Noetzel E, Bektas N, Schütz AK, Lue H, Lennartz B, Hartmann A, Dahl E, Bernhagen J. Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer. 2009 9:230. * (Highly accessed)
Abstract

Veeck J, Wild PJ, Fuchs T, Schüffler PJ, Hartmann A, Knüchel R, Dahl E. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer. 2009 9:217. * (Highly accessed)
Abstract

Jörissen H, Bektas N, Dahl E, Hartmann A, ten Haaf A, Di Fiore S, Kiefer H, Thess A, Barth S, Klockenbring T. Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer. Jörissen H, Bektas N, Dahl E, Hartmann A, ten Haaf A, Di Fiore S, Kiefer H, Thess A, Barth S, Klockenbring T. BMC Cancer. 2009 9:200. * (Highly accessed)
Abstract

Wiesmann F, Veeck J, Galm O, Hartmann A, Esteller M, Knüchel R, Dahl E. Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer. Breast Cancer Res. 2009 11:R34.
Abstract

Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, Berres ML, Zimmermann H, Streetz KL, Tacke F, Hillebrandt S, Schmitz P, Keppeler H, Berg T, Dahl E, Gassler N, Friedman SL, Trautwein C. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology. 2009 137:309-19.
Abstract

Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B, Hellebrand H, Engert S, Seitz S, Kreutzfeld R, Sasaki T, Arnold N, Schmutzler R, Kiechle M, Niederacher D, Harbeck N, Dahl E, Meindl A. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer. 2009 124:1727-35.
Abstract

Raman S, Fuchs TJ, Wild PJ, Dahl E, Roth V. The Bayesian Group-Lasso for Analyzing Contingency Tables. ACM International Conference Proceeding Series; Vol. 382 archive
Paper

Proceedings of the 26th Annual International Conference on Machine Learning. Montreal, Quebec, Canada. Pages: 881-888. Year of Publication: 2009. ISBN:978-1-60558-516-1
Link zu dem Paper: http://www.cs.mcgill.ca/~icml2009/papers/536.pdf

Videopräsentation: http://videolectures.net/icml09_raman_bgl/  

2008

Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knuchel R, Dahl E. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol Cancer. 2008 7:83. * (Highly accessed)
Abstract

Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knüchel R, Dahl E. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast Cancer Res. 2008 10:R82. * (Highly accessed)
Abstract

Lindemann-Docter K, Koufou SV, Dahl E, Jakse G, Knüchel R. [Nested-variant urothelial carcinoma : Case report and molecular aspects.] Pathologe. 2008 29:383-7. German.
Abstract

Bektas N, Noetzel E, Veeck J, Press MF, Kristiansen G, Naami A, Hartmann A, Dimmler A, Beckmann MW, Knüchel R, Fasching PA, Dahl E. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res. 2008 10:R58. * (Highly accessed)
Abstract

Gaisa NT, Donner A, V Serenyi S, Dahl E, Grosse J, Knüchel R. [Urothelial carcinoma in situ of the seminal vesicles - an indicator of tumour multifocality.] Gaisa NT, Donner A, V Serenyi S, Dahl E, Grosse J, Knüchel R. Pathologe. 2008 29:371-4. German.
Abstract

Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, Knuechel R, Dahl E.
Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer.
BMC Cancer. 2008 May 30;8(1):154. [Epub ahead of print]
Abstract

Gluz O, Wild P, Meiler R, Diallo-Danebrock R, Ting E, Mohrmann S, Schuett G, Dahl E, Fuchs T, Herr A, Gaumann A, Frick M, Poremba C,Nitz UA, Hartmann A.
Nuclear Karyopherin expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. Int J Cancer 2008. (in press) (IF 4,693)

Gaisa ND, Tilki D, Losen I, Dahl E, Stief CG, Knuechel R: Insights from a whole cystectomy specimen - association of primary small cell carcinoma of the bladder with urothelial carcinoma in situ.
Human Pathology. 2008 (in press) (IF 2,810)

Zafrakas M, Losen I, Knuechel R, Dahl E.
Enhancer of the rudimentary gene homologue (ERH) expression pattern in sporadic human breast cancer and normal breast tissue.
BMC Cancer. 2008 8:145 (IF 2,359)
Abstract

Veeck J, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knüchel R, Dahl E .
Epigenetic inactivation of the Secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis.
Carcinogenesis. 2008 Mar 19; [Epub ahead of print] (IF 5,366)
Abstract

Pilarsky C, Ammerpohl O, Sipos B, Dahl E, Hartmann A, Wellmann A, Braunschweig T, Löhr M, Jesnowski R, Friess H, Wente MN, Kristiansen G, Jahnke B, Denz A, Rückert F, Schackert HK, Klöppel G, Kalthoff H, Saeger HD, Grützmann R.
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling.
J Cell Mol Med. 2008 Feb 24; [Epub ahead of print] (IF 6,555)
Abstract

Bektas N, ten Haaf A, Veeck J, Wild PJ, Luescher-Firzlaff J, Hartmann A, Knuechel R and Dahl E.
Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer.
BMC Cancer. 2008 8:42 * (Highly accessed) (IF 2,359)
Abstract

Hamm A, Veeck J, Bektas N, Wild PJ, Hartmann A, Heindrichs U, Kristiansen G, Werbowetski-Ogilvie T, Del Maestro R, Knuechel R and Dahl E. Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: A systematic expression analysis. BMC Cancer. 2008 8:25 * (Highly accessed) (IF 2,359)
Abstract

Wasmuth HE, Zaldivar MM, Berres ML, Werth A, Scholten D, Hillebrandt S, Tacke F, Schmitz P, Dahl E, Wiederholt T, Hellerbrand C, Berg T, Weiskirchen R, Trautwein C, Lammert F:
The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection.
J Hepatol. 2008 48:208-15 (IF 6,073)
Abstract

Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Durst M, Kristiansen G, Wild PJ, Hartmann A, Knuechel R, Dahl E.
The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Oncogene. 2008 27:865-76 (IF 6,872)
Abstract

2007

Dahl E, Wiesmann F, Woenckhaus M, Stoehr R, Wild PJ, Veeck J, Knuchel R, Klopocki E, Sauter G, Simon R, Wieland WF, Walter B, Denzinger S, Hartmann A, Hammerschmied CG.
Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
Oncogene. 2007 Mar 12; [Epub ahead of print] (IF 6,872)
Abstract

Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Luscher B, Bernhagen J.
Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.
Oncogene. 2007 Feb 19; [Epub ahead of print] (IF 6,872)
Abstract

Jost E, do Ó N, Dahl E, Maintz CE, Jousten P, Habets L, Wilop S, Herman JG, Osieka R, Galm O.
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
Leukemia. 2007; advanced online publication. (IF 6,612)
Abstract

Fritzsche FR, Thomas A, Winzer KJ, Beyer B, Dankof A, Bellach J, Dahl E , Dietel M, Kristiansen G.
Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer.
Histol Histopathol. 2007 22:1221-30.
Abstract

Fritzsche FR, Dahl E, Dankof A, Burkhardt M, Pahl S, Petersen I, Dietel M, Kristiansen G.
Expression of AGR2 in non small cell lung cancer.
Histol Histopathol. 2007 22:703-8.
Abstract

Koensgen D, Mustea A, Klaman I, Sun P, Zafrakas M, Lichtenegger W, Denkert C, Dahl E, Sehouli J.
Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: Association with tumor progression.
Gynecol Oncol. 2007 Aug 13; [Epub ahead of print]
Abstract

Klinge U, Dahl E, Mertens PR.
Problem poser - how to interpret divergent prognostic evidence of simultaneously measured tumor markers?
Computational and Mathematical Methods in Medicine 2007 8:71-75.

2006

Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Durst M, Kristiansen G, Huszka C, Knuchel R, Dahl E.
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis.
Oncogene. 2006 25:3479-88. (IF 6,872)
Abstract

Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Duerst M, Klinkhammer-Schalke M, Blaszyk H, Knuechel R, Hartmann A, Rosenthal A, Wild PJ.
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin-alpha-2 (KPNA2) as a potential novel prognostic marker in breast cancer.
Clin. Cancer Res. 2006 12:3950-60 (IF 5,715)
Abstract

Fritzsche FR, Dahl E, Pahl S, Burkhardt M, Luo J, Mayordomo E, Gansukh T, Dankof A, Knuechel R, Denkert C, Winzer KJ, Dietel M, Kristiansen G.
Prognostic relevance of AGR2 expression in breast cancer.
Clin. Cancer Res. 2006; 12:1728-34. (IF 5,715)
Abstract

Chekerov R, Klaman I, Zafrakas M, Könsgen D, Mustea A, Petschke B, Lichtenegger W, Sehouli J, Dahl E.
Altered expression pattern of topoisomerase IIα (TOP2A) in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy
Neoplasia. 2006; 8:38-45. (IF 3,850)
Abstract | Full

Fritzsche F, Gansukh T, Borgono CA, Burkhardt M, Pahl S, Mayordomo E, Winzer KJ, Weichert W, Denkert C, Jung K, Stephan C, Dietel M, Diamandis EP, Dahl E , Kristiansen G.
Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status.
Br J Cancer. 2006; 94:540-47. (IF 4,115)
Abstract

Zafrakas M, Chorovicer M, Klaman I, Kristiansen G, Wild PJ, Heindrichs U, Knüchel R, Dahl E.
Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue.
Int J Cancer. 2006; 118:1453-59. (IF 4,700)
Abstract

Zafrakas M, Petschke B, Donner A, Fritzsche F, Kristiansen G, Knuechel R, Dahl E.
Expression analysis of Mammaglobin A (SCGB2A2) and Lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies.
BMC Cancer 2006; 6:88 (IF 1,992)
Abstract | Full

Fritzsche FR, Kristiansen G, Boesl A, Burkhardt M, Pahl S, Dankof A, Dietel M, Dahl E.
Tissue pretreatment with formic acid might lower HercepTest scores in breast cancer.
Diagn Mol Pathol. 2006; 15:237-42. (IF 2,104)

2005

Dahl E, Sadr-Nabavi A, Klopocki E, Betz B, Grube S, Kreutzfeld R, Himmelfarb M, Gelling S, Klaman I, Hinzmann B, Kristiansen G, Grützmann R, Kuner R, Petschke B, Rhiem K, Wiechen K, Sers C, Wiestler O, Schneider A, Höfler H, Nährig J, Dietel M, Schäfer R, Rosenthal A, Schmutzler R, Dürst M, Meindl A, Niederacher D.
Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer.
J Path 2005; 207:21-28. (IF 6,213)
Abstract

Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, Stephan C, Loening S, Bellach J, Dietel M, Rosenthal A
Expression profiling of microdissected matched prostate cancer samples reveals CD166 and CD24 as new prognostic markers for patient survival.
J Path 2004; 205:359-76. (IF 6,213)
Abstract

Kasper G, Weiser AA, Rump A, Sparbier K, Dahl E, Hartmann A, Wild P, Schwidetzky U, Castanos-Velez E, Lehmann K.
Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients.
Int J Cancer 2005; 117:961-73. (IF 4,700)
Abstract  

2004

Klopocki E, Kristiansen G, Wild P, Klaman I, Castanos-Velez E, Singer G, Stöhr R, Simon R, Sauter G, Leibiger H, Essers L,Weber B, Hermann K, Rosenthal A, Hartmann A, Dahl E.
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors.
Int J Oncology 2004; 25:641-649. (IF 2,681)
Abstract

Himmelfarb M, Klopocki E, Grube S, Staub E, Klaman I, Hinzmann B, Kristiansen G, Rosenthal A, Dürst M, Dahl E.
ITIH5, a novel member of the inter--trypsin inhibitor heavy chain family is downregulated in breast cancer.
Cancer Letters 2004; 204:69-77. (IF 3,049)
Abstract

Oberschmid BI, Dahl E, Dietmaier W, Hartmann A, Beatty B, Klopocki E, Hyman NH, Blaszyk H.
Distinct Secreted Frizzled Receptor Protein 1 staining pattern in patients with hyperplastic polyposis coli syndrome.
Arch Path Lab Med 2004; 128:967-973. (IF 1,587)
Abstract

Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, Rosenthal A, Pohlenz HD, Thierauch KH, Sommer A.
Shift of Syndecan-1 expression from epithelial to stromal cells during progression of solid tumors.
Eur J Cancer 2004; 40:1373-82. (IF 3,706)
Abstract

Stöhr R, Wissmann C, Suzuki H, Knüchel R, Krieg RC, Klopocki E, Dahl E, Wild P, Blaszyk H, Sauter G, Simon R, Schmitt R, Zaak D, Hofstädter F, Rosenthal A, Baylin SB, Pilarsky C, Hartmann A.
Deletions of chromosomes 8p and loss of SFRP1 expression are progression markers of papillary bladder cancer.
Lab Invest. 2004; 84:465-78. (IF 3,859)
Abstract | Full  

2003

Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M.
CD24 expression is a new prognostic marker in breast cancer.
Clin Cancer Res 2003; 9:4906-4913. (IF 5,715)
Abstract | Full

Liepinsh E, Barbals R, Dahl E, Sharipo A, Staub E, Otting G.
Death-domain fold of ASC PYRIN domain presents basis for PYRIN/PYRIN recognition.
J Mol Biol 2003; 332:1155-63. (IF 5,229)
Abstract

Grützmann R, Pilarsky C, Staub E, Schmitt AO, Förder M, Specht T, Hinzmann B, Dahl E, Alldinger I, Rosenthal A, Ockert D, Saeger HD.
Systematic isolation of genes differentially expressed in normal and cancerous tissue of the pancreas.
Pancreatology 2003; 3:169-178. (IF 1,564)
Abstract

2002

Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S.
CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival.
Am J Pathol 2002; 161:1215-21. (IF 5,796)
Abstract | Full

Kasper G, Taudien S, Staub E, Mennerich D, Rieder M, Hinzmann B, Dahl E , Schwidetzky U, Rosenthal A, Rump A.
Different structural organization of the encephalopsin gene in man and mouse.
Gene 2002; 295:27-32. (IF 2,694)
Abstract

2001

Staub E, Dahl E, Rosenthal A.
The DAPIN family: a novel domain links apoptotic and interferon response proteins.
Trends Biochem Sci 2001; 26:83-85. (IF 13,343)
Abstract

Sohl G, Theis M, Hallas G, Brambach S, Dahl E, Kidder G, Willecke K.
A new alternatively spliced transcript of the mouse connexin32 gene is expressed in embryonic stem cells, oocytes, and liver.
Exp Cell Res 2001; 266:177-86. (IF 4,148)
Abstract

2000 und früher

Schmitt AO, Specht T, Beckmann G, Dahl E, Pilarsky CP, Hinzmann B, Rosenthal A.
Exhaustive mining of EST libraries for genes differentially expressed in normal and tumour tissues.
Nucl Acids Res 1999; 27:4251-60. (IF 7,552)
Abstract | Full

Furumoto TA, Miura N, Akasaka T, Mizutani-Koseki Y, Sudo H, Fukuda K, Maekawa M, Yuasa S, Fu Y, Moriya H, Taniguchi M, Imai K, Dahl E, Balling R, Pavlova M, Gossler A, Koseki H.
Notochord-dependent expression of MFH1 and PAX1 cooperates to maintain the proliferation of sclerotome cells during the vertebral column development.
Dev Biol 1999; 210:15-29. (IF 5,234)
Abstract

Wilm B, Dahl E, Peters H, Balling R, Imai K.
Targeted disruption of Pax1 defines its null phenotype and proves haploinsufficiency.
Proc Natl Acad Sci U S A 1998; 95:8692-7. (IF 10,231)
Abstract | Full

Dahl E, Willecke K, Balling R.
Segment-specific expression of the gap junction gene connexin31 during hindbrain development.
Dev Genes Evol 1997; 207:359-361. (IF 2,549)
Abstract

Delorme B, Dahl E, Jarry-Guichard T, Briand JP, Willecke K, Gros D, Theveniau-Ruissy M.
Expression pattern of connexin gene products at the early developmental stages of the mouse cardiovascular system.
Circ Res 1997; 81:423-37. (IF 9,408)
Abstract | Full

Dahl E, Manthey D, Chen Y, Schwarz HJ, Chang YS, Lalley PA, Nicholson BJ, Willecke K.
Molecular cloning and functional expression of mouse connexin-30,a gap junction gene highly expressed in adult brain and skin.
J Biol Chem 1996; 271:17903-10. (IF 5,854)
Abstract | Full

Reuss B, Hellmann P, Dahl E, Traub O, Butterweck A, Grummer R, Winterhager E.
Connexins and E-cadherin are differentially expressed during trophoblast invasion and placenta differentiation in the rat.
Dev Dyn 1996; 205:172-82. (IF 3,333)
Abstract

Dahl E, Winterhager E, Reuss B, Traub O, Butterweck A, Willecke K.
Expression of the gap junction proteins connexin31 and connexin43 correlates with communication compartments in extraembryonic tissues and in the gastrulating mouse embryo, respectively.
J Cell Sci 1996; 109:191-7. (IF 6,543)
Abstract | Full

Delorme B, Dahl E, Jarry-Guichard T, Marics I, Briand JP, Willecke K, Gros D, Theveniau-Ruissy M.
Developmental regulation of connexin 40 gene expression in mouse heart correlates with the differentiation of the conduction system.
Dev Dyn 1995; 204:358-71. (IF 3,333)
Abstract

Dahl E, Winterhager E, Traub O, Willecke K.
Expression of gap junction genes, connexin40 and connexin43, during fetal mouse development.
Anat Embryol (Berl) 1995; 191:267-78. (IF 1,255)
Abstract

Hennemann H, Dahl E, White JB, Schwarz HJ, Lalley PA, Chang S, Nicholson BJ, Willecke K.
Two gap junction genes, connexin 31.1 and 30.3, are closely linked on mouse chromosome 4 and preferentially expressed in skin.
J Biol Chem 1992; 267:17225-33. (IF 5,854)
Abstract | Full

Schwarz HJ, Chang YS, Hennemann H, Dahl E, Lalley PA, Willecke K.
Chromosomal assignments of mouse connexin genes, coding for gap junctional proteins, by somatic cell hybridization.
Somat Cell Mol Genet 1992; 18:351-9. (IF nicht gefunden)
Abstract

Hennemann H, Suchyna T, Lichtenberg-Frate H, Jungbluth S, Dahl E, Schwarz J, Nicholson BJ, Willecke K.
Molecular cloning and functional expression of mouse connexin40, a second gap junction gene preferentially expressed in lung.
J Cell Biol 1992; 117:1299-310. (IF 10,951)
Abstract | Full

Hennemann H, Kozjek G, Dahl E, Nicholson B, Willecke K.
Molecular cloning of mouse connexins26 and -32: similar genomic organization but distinct promoter sequences of two gap junction genes.
Eur J Cell Biol 1992; 58:81-9. (IF 2,195)
Abstract

Willecke K, Heynkes R, Dahl E, Stutenkemper R, Hennemann H, Jungbluth S, Suchyna T, Nicholson BJ
Mouse connexin37: cloning and functional expression of a gap junction gene highly expressed in lung.
J Cell Biol 1991; 114:1049-57. (IF 10,951)
Abstract | Full

Willecke K, Jungbluth S, Dahl E, Hennemann H, Heynkes R, Grzeschik KH
Six genes of the human connexin gene family coding for gap junctional proteins are assigned to four different human chromosomes.
Eur J Cell Biol 1990; 53:275-80. (IF 2,195)
Abstract

Pilarsky CP, Schmitt, AO, Dahl E, Rosenthal A.
Microarrays-chances and challenges.
Current Opinion in Molecular Therapeutics 1999; 1:727-736. (IF 2,701)

Dahl E, Koseki H, Balling R.
Pax genes and organogenesis. (Unter den meistzitierten Reviews* im Zitationsvergleich 1997 bis 1999 der Entwicklungsbiologie)
Bioessays 1997; 19:755-65. (IF 6,787)

Willecke K, Hennemann H, Dahl E, Jungbluth S, Heynkes R.
The diversity of connexin genes encoding gap junctional proteins.
Eur J Cell Biol 1991; 56:1-7. (IF 2,195)

___________________________________________
 * Externe Links öffnen sich in neuem Fenster.

______________________________________________________________________

Institut für Pathologie » Forschung » AG Molekulare Onkologie

| Leitung | Team | Zielsetzung | Projekte | Aktuell | Methoden | Publikationsliste | Kooperationspartner | Links |

Aktuelle Stellenausschreibungen: [1 (neue Ausschreibung) ]   [2] [3] [4] [5] [6] | [1]